文献速递白血病造血干细胞移植与细胞治疗

靶向HA-1的T细胞受体T细胞疗法治疗造血干细胞移植后复发性白血病

HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
PubMed 文献 · Blood · 2024-01-01

本文报告一项1期临床试验,用靶向次要组织相容性抗原HA-1的TCR-T产品治疗或巩固治疗造血干细胞移植(HCT)后持续或复发的白血病及髓系肿瘤;9例HCT后复发受者接受淋巴清除化疗后输注HA-1 TCR-T,未发生剂量限制性毒性,4例达到或维持完全缓解,1例缓解持续>2年。

要点

  • 9例HCT后复发的受者接受淋巴清除化疗后输注HA-1 TCR-T,未发生剂量限制性毒性。
  • TCR-T细胞过继输注后在体内扩增并持续存在。
  • 研究未设计为评估疗效,但4例达到或维持完全缓解,1例缓解持续>2年。

核心结论

  • HA-1 TCR-T疗法看来可行且安全,并显示出初步的疗效信号。

研究设计与样本

  • 一项1期临床试验,采用靶向次要组织相容性抗原HA-1的新型TCR-T产品,治疗或巩固治疗持续或复发的白血病及髓系肿瘤。
  • 主要目的是评估HCT后给予HA-1 TCR-T的可行性与安全性。
  • 从HA-1不合的HCT供者成功制备表达HA-1 TCR和CD8共受体的CD8+与CD4+ T细胞。
  • 9例HCT后出现疾病复发的受者在淋巴清除化疗后接受1次或多次HA-1 TCR-T输注。
  • 该试验在ClinicalTrials.gov注册,注册号为NCT03326921。

主要发现

  • TCR-T细胞过继输注后在体内扩增并持续存在。
  • 未发生剂量限制性毒性。
  • 尽管研究未设计为评估疗效,4例患者在淋巴清除和HA-1 TCR-T后达到或维持完全缓解,其中1例在>2年时仍处于缓解。
  • 对TCR-T治疗后复发或进展的白血病行单细胞RNA测序,发现与T细胞功能障碍或癌细胞生存相关的分子上调。

局限性

  • 尽管研究未设计为评估疗效,4例患者达到或维持完全缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. We conducted a phase 1 clinical trial using a novel TCR-T product targeting the minor H antigen, HA-1, to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms. The primary objective was to evaluate the feasibility and safety of administration of HA-1 TCR-T after HCT. CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors. One or more infusions of HA-1 TCR-T following lymphodepleting chemotherapy were administered to 9 HCT recipients who had developed disease recurrence after HCT. TCR-T cells expanded and persisted in vivo after adoptive transfer. No dose-limiting toxicities occurred. Although the study was not designed to assess efficacy, 4 patients achieved or maintained complete remissions following lymphodepletion and HA-1 TCR-T, with 1 patient still in remission at >2 years. Single-cell RNA sequencing of relapsing/progressive leukemia after TCR-T therapy identified upregulated molecules associated with T-cell dysfunction or cancer cell survival. HA-1 TCR-T therapy appears feasible and safe and shows preliminary signals of efficacy. This clinical trial was registered at ClinicalTrials.gov as #NCT03326921.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Krakow EF, Brault M, Summers C, et al. HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood. 2024. PMID: 38683966. doi:10.1182/blood.2024024105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。